Corbus Pharmaceuticals(CRBP) - 2024 Q1 - Quarterly Results

Exhibit 99.1 Corbus Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update • Phase 1 data for CRB-701 (SYS6002) to be presented at ASCO Annual Meeting on June 1, 2024 CRB-701: CRB-701 (SYS6002) is a next-generation antibody drug conjugate targeting Nectin-4 that contains a sitespecific, cleavable linker and a homogenous drug antibody ratio of 2 using MMAE as the payload. Nectin-4 is a clinically validated, tumor-associated antigen in urothelial cancer. CRB-913 is a second ...